

Effectiveness of early vocational rehabilitation versus usual care to support RETurn to work after stroke: A pragmatic, parallel-arm multicenter, randomized controlled trial

International Journal of Stroke

1–15

© 2024 World Stroke Organization



Article reuse guidelines:

sagepub.com/journals-permissions

DOI: 10.1177/17474930241306693

journals.sagepub.com/home/wso



KA Radford¹, A Wright-Hughes², E Thompson², DJ Clarke³,
J Phillips¹, J Holmes¹, K Powers¹, D Trusson¹, K Craven¹, C Watkins⁴,
A Bowen⁵, C McKeivitt⁶, J Stevens⁷, JD Murray⁸, RJ O'Connor⁹,
S Pyne¹⁰, H Risebro¹⁰, R Cameron¹⁰, TH Sach^{10,11}, F Day² and AJ Farrin²;
On behalf of the RETAKE Research group

Abstract

Background: Return-to-work is a major goal achieved by fewer than 50% stroke survivors. Evidence on how to support return-to-work is lacking.

Aims: This study aimed to evaluate the clinical effectiveness of Early Stroke Specialist Vocational Rehabilitation (ESSVR) plus usual care (UC) (i.e. usual NHS rehabilitation) versus UC alone for helping people return-to-work after stroke.

Methods: This pragmatic, multicentre, individually randomized controlled trial with embedded economic and process evaluations compared ESSVR with UC in 21 NHS stroke services across England and Wales. Eligible participants were aged ≥ 18 years, in work at stroke onset, hospitalized with new stroke and within 12 weeks of stroke. People not intending to return-to-work were excluded. Participants were randomized (5:4) to individually tailored ESSVR delivered by stroke specialist occupational therapists for up to 12 months or usual National Health Service rehabilitation. Primary outcome was self-reported return-to-work for ≥ 2 h per week at 12 months. Primary and safety analyses were done in the intention-to-treat population.

Results: Between 1 June 2018, and 7 March 2022, 583 participants (M_{age} 54.1 years (SD 11.0), 69% male) were randomized to ESSVR ($n=324$) or UC ($n=259$). Primary outcome data were available for 454 (77.9%) participants. Intention-to-treat analysis showed no evidence of a difference in the proportion of participants returned-to-work at 12 months (165/257 (64.2%) ESSVR vs 117/197 (59.4%) UC; adjusted odds ratio 1.12 (95% CI: 0.75–1.68), $p=0.5678$). There was some indication that older participants and those with more post-stroke impairment were more likely to benefit from ESSVR (interaction $p=0.0239$ and $p=0.0959$, respectively).

Conclusion: To our knowledge, this is the largest trial of a stroke vocational rehabilitation (VR) intervention ever conducted. We found no evidence that ESSVR conferred any benefits over UC in improving return-to-work rates 12 months post-stroke. Return-to-work (for at least 2 h per week) rates were higher than in previous studies (64.2% ESSVR vs 59.4% UC) at 12 months and more than double that observed in our feasibility trial (26%). Interpretation of findings was limited by a predominantly mild–moderate sample of participants and the COVID-19 pandemic. The pandemic impacted the trial, ESSVR and UC delivery, altering the work environment and employer behavior. These changes influenced our primary outcome and the meaning of work in people's lives; all pivotal to the context of ESSVR delivery and its mechanisms of action.

Data access: Data available on reasonable request.

Registration: ISRCTN12464275.

Keywords

Stroke, work, rehabilitation, occupational therapy, randomized controlled trial

Received: 1 August 2024; accepted: 14 November 2024

Introduction

In the United Kingdom, stroke occurs in more than 100,000 people per year,¹ with increasing incidence among working-age people² and stroke-related productivity losses estimated to reach £2.1 billion by 2025.³ Although reported rates vary, only approximately half UK stroke survivors return-to-work by 1 year.^{4,5} Work is a human right and central to identity providing income, and a sense of purpose.⁶ Good work is protective of health, well-being, and longevity.^{7,8}

Government policy and clinical guidelines^{9–11} recognize the need to support stroke survivors of all ages to return-to-work. Vocational rehabilitation (VR) enables people who develop health conditions to overcome obstacles to accessing, maintaining, or returning-to-work or other meaningful occupation.¹² However, there is little evidence of the effectiveness of post-stroke VR interventions.¹³ A single South African trial (n=80) of a 6-week occupational therapist (OT) and physiotherapist workplace intervention, reported more intervention participants returned-to-work (60%) at 6-months post-stroke than usual care (UC) (20%).¹⁴ Our single-center feasibility trial in 46 stroke survivors found that Early Stroke Specialist Vocational Rehabilitation (ESSVR) could be delivered in people with a range of post-stroke disability (37% moderate or moderate-severe stroke),^{15,16} with 39% versus 26% of controls returned-to-work at 12 months (paid/unpaid $\geq$ 1-h per week or full-time education).

Aims

We conducted the RETurn-to-work After strokeKE (RETAKE) trial to test the clinical effectiveness of ESSVR on stroke survivors' return-to-work at 12 months.

Methods

Study design and participants

RETAKE was a pragmatic, multicentre, researcher-blinded, individually randomized controlled, partially

nested, superiority trial of occupational-therapy-led ESSVR plus UC versus UC alone conducted in 21 English and Welsh NHS stroke services.¹⁷ An eight-site internal pilot assessed recruitment after 6 months and follow-up after another 6 months. An embedded cost-effectiveness¹⁸ and process evaluation are reported separately.^{19–24} Patient and public involvement (PPI) throughout provided valuable contributions to trial design, documentation, progress, and outputs. The methods have been reported in detail elsewhere^{17,25} and undertaken after appropriate NHS ethical approval (East Midlands—Nottingham 2 Research Ethics Committee Ref: 18/EM/0019).

Eligible participants were adults ($\geq$ 18 years of age), admitted to hospital with new stroke and in work (paid/unpaid $\geq$ 2 h per week) at stroke onset. Those not intending to return-to-work were excluded. Nominated and eligible carers (main informal caregiver, providing support once or more per week) could join the study. Stroke survivors and carers had to be willing and with capacity to provide informed consent to participate in the study, and sufficient English to contribute to data collection. Written informed consent was required, or verbal consent observed by an independent witness if unable to sign their name or mark the consent form.

Stroke services were eligible if they had capacity to deliver ESSVR and were not routinely providing well-defined VR within 12 weeks of stroke. OTs experienced in delivering specialist stroke rehabilitation in community settings were preferred.

Randomization and masking

Participants were randomly assigned to ESSVR or UC sequentially, with 5:4 allocation ratio to account for the partially nested study design (participants nested within OTs in ESSVR). Allocation was via a computer-generated minimization program incorporating random element, stratified by site, participant age (< 55 , ≥ 55 years) and stroke severity (derived from EQ-5D-5L mobility question, picture

¹Centre for Rehabilitation and Ageing Research, School of Medicine, Medical School Queen's Medical Centre, Nottingham, UK

²Clinical Trials Research Unit, Leeds Institute for Clinical Trials Research, University of Leeds, Leeds, UK

³Academic Unit for Ageing and Stroke Research, Leeds Institute of Health Sciences, University of Leeds, Leeds, UK

⁴Applied Health Research hub and School of Nursing and Midwifery, University of Central Lancashire, Preston, UK

⁵Manchester Centre for Health Psychology, Geoffrey Jefferson Brain Research Centre, Division of Psychology & Mental Health, University of Manchester, Manchester, UK

⁶Division of Health and Social Care Research, King's College London, London, UK

⁷PPI, UK

⁸Different Strokes, London, UK

⁹Academic Department of Rehabilitation Medicine, University of Leeds, Leeds, UK

¹⁰Norwich Medical School, University of East Anglia, Norwich, UK

¹¹School of Primary Care, Population Sciences and Medical Education, University of Southampton, Southampton, UK

Corresponding author:

A Wright-Hughes, Clinical Trials Research Unit, Leeds Institute for Clinical Trials Research, University of Leeds, Leeds LS2 9JT, UK.

Email: medawri@leeds.ac.uk

naming, and executive tasks from the Oxford Cognitive Screen (OCS)).²⁶ Blinding of participants and OTs was not possible. Researchers were masked to allocation.

Procedures

Following admission into a stroke service, screening, informed consent, and baseline assessments will be completed within 12 weeks of stroke onset, prior to randomization and allocation.

ESSVR was developed according to the Medical Research Council (MRC) framework for complex interventions^{24,27} and underwent prior feasibility testing.^{15,16} ESSVR was delivered by specially trained RETAKE OTs using a case-coordination model of early intervention VR up to 12 months post-randomization. ESSVR was originally designed for in-person delivery at the participants home, work or in the community, later adapted to remote delivery because of the pandemic. ESSVR was individually tailored according to the participants' needs, preferences, and employment context; it included assessing the impact of stroke on the job, educating patients and employers about stroke impact, work preparation, and liaison with employers. RETAKE OTs training, intervention delivery, mentoring, and Competency assessment are described elsewhere.^{20–23,28,29} UC was offered to participants in both trial arms according to site's available routine rehabilitation services. RETAKE OTs could not provide treatment to UC participants to prevent contamination. UC data were self-reported using participant questionnaires.

Researchers collected baseline demographics, details of stroke, and the OCS²⁶ to assess major cognitive domains. Questionnaires capturing patient- and carer-reported measures were administered by post or online at baseline and 3-, 6-, and 12-month post-randomization. Priming calls, reminder letters/emails, and SMS text message prompts supported data return. Two-way SMS text messages were sent to non-responders to confirm return-to-work only (the primary outcome), followed by a telephone call or face-to-face home visit. Primary 12-month return-to-work outcome data were collected retrospectively from non-responders latterly in the overall trial follow-up period. We intended to obtain aggregated work status via routine data transfers from the Department for Work and Pensions (DWP).

Outcomes

The primary outcome was self-reported return-to-work status at 12-month post-randomization. "In" work, meant participants were in paid or unpaid work (including pre-stroke, new, or adapted roles) for at least 2 h per week.

Secondary outcomes, participant self-reported at 3-, 6- and 12-month post-randomization (unless stated otherwise), included:

- return-to-work at 3 and 6 months;
- changes in role, hours worked per week, and days in work following return-to-work;
- mood (Hospital Anxiety and Depression Scale (HADS));³⁰
- functional ability (Nottingham Extended Activities of Daily Living (NEADL));³¹
- social participation (Community Integration Questionnaire (CIQ) social and productivity scores)³² at 12 months;
- work self-efficacy (single question from the work ability index (WAI));³³
- confidence (Confidence After Stroke Measure (CASM))³⁴ at 12 months;
- carer burden (Modified Caregiver Strain Index (MSCI)).³⁵

Adverse events included death (reported by site), hospital attendances, and work accidents (participant self-report).

Usual care

Our approach to understanding UC in the context of this trial was threefold and described elsewhere;²⁵ (1) Self-reported resource use data were collected from participants at each follow-up, (2) an embedded case study design and for a randomly selected 5% of participants in both arms involving repeated (a) observation of intervention delivered and (b) interviews with participants, treating therapists' and participants' employers (where permitted), (c) extracted detail from UC therapy records, SNAPP data, and participants' self-reported resource use to establish a "complete" picture, (3) survey of participating sites pre- and post-recruitment to understand UC pathways and VR service developments in the trial lifetime.

Statistical analysis

We estimated 760 participants (420 ESSVR, 340 UC) would provide 90% power with two-sided 5% significance level to detect a 13% absolute difference in the proportion of people meeting the primary outcome, allowing for 20% loss to follow-up. This assumed 26% return-to-work in UC as per our feasibility study¹⁵ and an average cluster size of 11 ESSVR participants per OT (0.68 coefficient of variation), 0.03 intracluster correlation. Due to the pandemic, the sample size target was reduced to 582 participants (308 ESSVR, 274 UC) to provide 80% power, with updated average cluster size assumption of seven participants per OT.

We analyzed effectiveness outcomes according to the intention-to-treat population, defined as all participants randomly allocated, regardless of adherence. All statistical testing used two-sided 5% significance levels and were conducted in SASv9.4. We undertook single final analysis

of outcome data (including internal pilot data) with no interim analyses.

We analyzed the primary outcome using a generalized logistic mixed-effects partially nested regression model,³⁶ adjusted for site, age, gender, mobility, OCS picture naming (aphasia) and OCS executive mixed scores (cognition) as fixed effects, and OT random effect (see Supplementary materials), to test for differences between treatment groups on 12-month return-to-work status. We analyzed secondary outcomes similarly using logistic or linear regression adjusted for respective baseline score, as appropriate. Results were expressed as adjusted odds ratios (OR, ESSVR/UC) or mean differences (MD, ESSVR/UC), together with 95% CIs and p-values. Assumptions were checked for all regression models using residual plots. Missing data were imputed by treatment group via multiple imputation by chained equations with 50 imputations, including fixed covariates, variables predictive of missingness, and outcome at preceding time-points (see Supplementary materials). Results of identical analyses performed on each of the imputed datasets were combined using Rubin's rules. Sensitivity analyses used complete data.

Prespecified exploratory moderator analyses of the primary outcome investigated whether the treatment effect varied by covariates, number of impairments, role, pre-stroke working hours, recruitment period, and baseline questionnaire scores, by including a treatment-moderator interaction in the primary analysis model. Further exploratory analysis explored the impact of participant intervention adherence using complete data in a complier average causal effect analysis and by excluding non-compliers.

Results

Between 1 June 2018, and 7 March 2022, 3672 patients were screened, and 583 participants randomly assigned to ESSVR ($n=324$) and UC ($n=259$) (Figure 1). Carers were recruited for 137 (23.5%) participants. Due to the pandemic, recruitment was paused 31 March to 1 August 2020. Most participants were recruited pre-COVID (76.3%), but the trial completed for only 28.5%; 12.3% were recruited during and 11.3% after the UK Coronavirus Job Retention (furlough) scheme applied.³⁷ The impact of COVID on trial participants is summarized in Tables S7–8.

Baseline characteristics were balanced across arms (Table 1, Table S1–3). Participants were mostly male (400, 69.0%), White (453, 83.7%), with mean age 54 years (SD 11.1); compared to 52.1% male, mean age 64.2 years (SD 15.8) screened (Table S1). Participants were well educated (41.7% higher education, i.e. university degree or equivalent) and worked in an equal mix of blue- and white-collar roles. Participants were mostly ischemic stroke survivors (82.8%), recruited a median 28 days post-stroke (IQR 13–44) having spent a median 4 days in hospital (IQR 2–10).


Half had no pre-stroke comorbidities known to affect work. Half had no or mild post-stroke impairments in mobility (EQ-5D-5L indicated no/only slight problems walking), cognition (OCS executive mixed task score $\leq 4/13$), or expressive language (OCS picture naming task score $\leq 3/4$) and only 10.6% had more than one of these impairments, indicative of a mostly mild-moderate severity sample.

Primary 12-month return-to-work outcome data were completed for 454/583 (77.9%) participants. Greater loss-to-follow-up occurred for secondary outcomes; 316/583 (54.2%) participants returned full 12-month questionnaires, and carer burden was available for only 54/137 (39.4%). Participants lost-to-follow-up (any timepoint) had less favorable baseline characteristics (i.e. impairments, length of hospital stay) and were more likely to have been recruited pre-COVID, female, older, non-White ethnicity, in blue-collar roles, not in paid employment, not in a relationship, living alone, and without a recruited carer. Where primary outcome data were available, participants missing secondary outcomes were less likely to have returned-to-work. Results indicated differential missing data patterns by arm (Figure S1–2). Eligibility violations (in $<1\%$ participants), contamination (1.5%), unblinding (4.8%), withdrawals (6.0%), and deaths ($<1\%$) are detailed in Table S4.

The intervention commenced in 309/324 (95.4%) ESSVR participants, 244 (75.3%) were deemed to have complied,²⁴ and participants attended a median 7 (IQR 4–12) sessions over 10.3 months (IQR 5.5–12.0). Median time to commence ESSVR was 9 (IQR 6–13) days post-randomization; 38 (IQR 23–56) days post-stroke. Of those commencing ESSVR, 246 (82.3%) had at least one in-person session at home, 67 (22.4%) at work, 31 (10.4%) in the community, 243 (81.3%) via telephone/video call, and 52 (17.4%) in hospital. Only 119 (40.3%) consented to OT contact with their employer, 67 (22.7%) had no employer or were self-employed and 74 (25.0%) had in-person or online employer visits. However, 60 OTs were trained and 48 delivered ESSVR for at least one participant, treating a median 6 participants (range 1–16). Analysis of ESSVR records for 39 participant-OT pairs showed OTs delivered ESSVR with acceptable overall fidelity,^{21,22} but lower fidelity to employer and family engagement.

Across methods used to capture UC,^{23,25} findings suggest there was little overall difference in health resource utilization between the ESSVR and UC groups. However, there were slightly more counselor, Speech and Language Therapy (SLT), social worker, and rehabilitation assistant appointments in the UC group, while the ESSVR group had more appointments with OTs, physiotherapist, General Practitioners (GPs), district nurses, and health care assistants. The number of secondary care outpatient visits was similar between the two groups. Inpatient stays were slightly more frequent in UC.¹⁸ Interview data from UC and ESSVR participants consistently identified UC provision

Figure 1. CONSORT Diagram.



as typically of short duration (range 2–8 weeks), predominantly focused on treating physical impairments rather than work goals. It was also perceived as poorly coordinated with limited communication between treating therapists and between therapists and participants.^{19,23}

On the 12-month primary outcome, 282/454 (62.1%) participants reported return-to-work of at least 2 h a week, 165/257 (64.2%) in ESSVR and 117/197 (59.4%) in UC, with equal proportions of participants on graded return-to-work. The adjusted OR 1.12 (95% CI 0.75–1.68, $p=0.5678$) of return-to-work in ESSVR versus UC provided no

evidence that ESSVR was superior to UC (Table 2). Younger participants (OR 0.97 per year, 95% CI: 0.96–0.99, $p=0.0120$), those with better mobility (OR 1.43, 95% CI: 1.20–1.72, $p<0.0001$) and cognition (OR 1.09, 95% CI: 1.02–1.16, $p=0.0081$) were more likely to return-to-work (Table S6, Figure S4). Adjusted ORs of return-to-work in ESSVR versus UC were similar at 3 and 6 months, and there were no changes in conclusions in sensitivity analysis of complete data at 12 months (Table S5) or in analysis excluding non-compliers (135/201, 67.2% intervention compliers vs 30/56, 53.6% intervention

Table 1. Baseline Characteristics*.

N (%)	ESSVR (n = 324)	UC (n = 259)	Total (n = 583)
Recruitment period			
Pre-COVID < 31 Mar 2020	248 (76.5%)	197 (76.1%)	445 (76.3%)
12-m pre-COVID < 31 Mar 2019	93 (28.7%)	73 (28.2%)	166 (28.5%)
During furlough scheme < 30 Sep 2021	38 (11.7%)	34 (13.1%)	72 (12.3%)
Post-furlough > 30 Sep 2021	38 (11.7%)	28 (10.8%)	66 (11.3%)
Location of assessment			
Hospital	152 (47.6%)	121 (47.8%)	273 (47.7%)
Home	165 (51.7%)	130 (51.4%)	295 (51.6%)
Age, mean (SD)	53.7 (10.48)	54.3 (11.88)	54.0 (11.12)
Male	235 (72.8%)	165 (64.2%)	400 (69.0%)
Ethnicity			
White	254 (84.1%)	199 (83.3%)	453 (83.7%)
Black	19 (6.3%)	23 (9.6%)	42 (7.8%)
Asian	13 (4.3%)	12 (5.0%)	25 (4.6%)
Mixed	2 (0.7%)	2 (0.8%)	4 (0.7%)
Other	14 (4.6%)	3 (1.3%)	17 (3.1%)
Living with another	244 (75.5%)	203 (79.0%)	447 (77.1%)
Married/long-term relationship	212 (65.8%)	183 (71.2%)	395 (68.2%)
Carer recruited	71 (21.9%)	66 (25.5%)	137 (23.5%)
Highest qualification			
Higher education	129 (40.8%)	108 (42.9%)	237 (41.7%)
Further education	93 (29.4%)	75 (29.8%)	168 (29.6%)
Job type			
Blue collar	156 (51.5%)	120 (50.2%)	276 (50.9%)
White collar	147 (48.5%)	119 (49.8%)	266 (49.1%)
In paid/self-employment pre-stroke	301 (94.7%)	234 (94.4%)	535 (94.5%)
Pre-stroke working hours, Mean (SD)	38.3 (12.88)	37.7 (12.65)	38.1 (12.78)
Type of stroke			
Subarachnoid hemorrhage	8 (2.6%)	1 (0.4%)	9 (1.6%)
Intracerebral hemorrhage	48 (15.5%)	37 (15.6%)	85 (15.6%)
Ischemic stroke	253 (81.9%)	199 (84.0%)	452 (82.8%)
Length of hospital stay (days), Median (IQR)	4.0 (2.0, 10.0)	4.0 (2.0, 10.0)	4.0 (2.0, 10.0)
Days from stroke to randomization, Median (IQR)	28.0 (112.0, 46.0)	29.0 (13.0, 42.0)	28.0 (13.0, 44.0)

(Continued)

Table 1. (Continued)

N (%)	ESSVR (n=324)	UC (n=259)	Total (n=583)
Comorbidities			
Cardiac complications	65 (20.1%)	64 (24.9%)	129 (22.2%)
Mental health problems	29 (9.0%)	26 (10.1%)	55 (9.5%)
Seizures	6 (1.9%)	6 (2.3%)	12 (2.1%)
Musculoskeletal conditions	54 (16.7%)	39 (15.2%)	93 (16.0%)
Diabetes	59 (18.3%)	40 (15.6%)	99 (17.1%)
None	165 (51.1%)	130 (50.6%)	295 (50.9%)
Post-stroke impairments			
None	161 (49.7%)	134 (51.7%)	295 (50.6%)
One	131 (40.4%)	95 (36.7%)	226 (38.8%)
Multiple	32 (9.9%)	30 (11.6%)	62 (10.6%)
Type of impairment			
Mobility [†]	119 (36.7%)	91 (35.1%)	210 (36.0%)
Aphasia [‡]	53 (16.4%)	48 (18.5%)	101 (17.3%)
Cognitive [§]	32 (9.9%)	21 (8.1%)	53 (9.1%)

*Missing: n=11 location (other n=4), n=42 ethnicity, n=3 living arrangements, n=4 marital status, n=15 education, n=41 job type, n=37 type of stroke, n=208 length of stay, n=3 time since stroke, n=3 comorbidities.

[†]Mobility impairment=Eq-5D-5L moderate–severe problems walking about/unable to walk.

[‡]Aphasia impairment=OCS picture naming task score $\leq 3/4$ ($\leq$ 5th centile of normative data on expressive language).

[§]Cognitive impairment=OCS executive mixed task scores $\leq 4/13$ ($\leq$ 5th centile of normative data on Task switching/Attention).


non-compliers reported having returned-to-work). Prespecified exploratory subgroup analyses found good evidence of a differential treatment effect on the primary outcome according to participants' age (interaction $p=0.0239$). Older participants were more likely to benefit from ESSVR, and; less likely to return-to-work in UC but not ESSVR (Figure 2, Figure S4). There was some indication that participants with more post-stroke impairment were more likely to benefit from ESSVR (interaction $p=0.0959$).

In participants who had returned-to-work at 12 months (Table 2), 41/103 (39.8%) ESSVR versus 24/75 (32.0%) UC participants reported a change in working hours, of whom the mean weekly hours were reduced in ESSVR (28.4, SD 11.65) compared to UC (31.5, SD 11.71). A similar pattern was observed at 3 and 6 months but with a decreasing proportion of participants with changes in working hours and increased working hours over time. At 12 months, more ESSVR participants (22/98, 22.4%) reported having taken time off due to their stroke over the

past 3 months compared to UC (14/72, 19.4%), and 13/103 (12.6%) ESSVR versus 9/76 (11.8%) UC participants reported a change in role.

Other secondary outcomes (Table 3, Figure S3) were largely similar, with small differences between trial arms and provided no evidence that ESSVR was superior to UC. However, participants tended to have slightly improved outcomes in UC compared to ESSVR, and UC participants reported statistically significantly better functional ability (NEADL: MD -3.37 , 95% CI -6.26 to -0.48 , $p=0.0230$) and carer burden (MSCI: MD 2.52 , 95% CI 0.63 to 4.41 , $p=0.0095$) at 12 months in multiply imputed analyses. Statistically significant effects were not observed at other timepoints, or in sensitivity analysis (Table S4) and should be interpreted with caution given substantial loss-to-follow-up. For further exploratory comparison of secondary outcomes, see Table S9.

There were no Related and Unexpected Serious Adverse Events. Self-reported safety outcomes were similar for both groups (Table S10).

Figure 2. Forest plot depicting exploratory subgroup analyses.

Discussion

Main findings

In stroke survivors working at stroke onset, we found no quantitative evidence of benefit of ESSVR over UC in self-reported return-to-work, mood, functional ability, social participation, work self-efficacy, post-stroke confidence, or carer burden. These findings are in a predominantly male (69%, consistent with UK stroke registry data),⁴ relatively young (mean 54 years) and mild-to-moderate sample of stroke survivors. The study was conducted during a pandemic, a period marked by significant changes in UK work practices (see supplementary material for further reflection) and results are influenced by high levels of missing data for secondary outcomes and some limitations in employer engagement.

Although 5% more ESSVR than UC participants returned-to-work (64.2% vs 59.4%), this was not statistically significant. More UC participants returned-to-work than expected, more than double that observed in our feasibility trial (26%). Possibly due to case-mix, pandemic effects, and recent evidence suggesting higher rates, in younger stroke survivors, motivated to return-to-work.³⁸

Only 11% of RETAKE participants had more than one impairment in mobility, cognition, or expressive language indicative of a mild-moderate severity sample. Participants were also predominantly male, White, well educated, and half were employed in white-collar roles. All were significant predictors of return-to-work.³⁸ These stroke survivors

may be capable of self-advocating and navigating return-to-work without intensive ESSVR support.

Exploratory subgroup analyses found ESSVR was more likely to benefit people disadvantaged by age and impairment. However, further research is required to confirm these findings.

In participants who returned-to-work, more ESSVR participants reported changes in working hours and taking time off compared to UC, suggesting ESSVR might influence return to modified work, possibly enabling those who might not otherwise return-to-work to do so, or ensuring work is sustainable and work-life balanced maintained.

Our finding of slightly improved outcomes in UC compared to ESSVR on secondary outcomes, particularly 12-month functional ability and carer burden, should be interpreted with caution. Improvements largely represented very small effect sizes $< 0.2^{39}$ and were unreliable due to high levels of missing data.

Strengths

Despite challenges recruiting to multicentre stroke trials⁴⁰ and a global pandemic, this first, large, powered, UK trial of ESSVR achieved our revised target, and almost 80% follow-up of primary 12-month return-to-work outcomes.

Inclusion criteria were broad, aiming to support return-to paid or unpaid work irrespective of age recognizing increases in state pension age, the value of work to health and its meaning in people's lives.⁶

Table 2. Primary and secondary return-to-work outcomes.

	3 months			6 months			12 months		
	ESSVR (n = 324)	UC (n = 259)	Total (n = 583)	ESSVR (n = 324)	UC (n = 259)	Total (n = 583)	ESSVR (n = 324)	UC (n = 259)	Total (n = 583)
Primary outcome available	220 (67.9%)	156 (60.2%)	376 (64.5%)	227 (70.1%)	156 (60.2%)	383 (65.7%)	257 (79.3%)	197 (76.1%)	454 (77.9%)
Primary outcome: Return-to-work									
Yes	133 (60.5%)	95 (60.9%)	228 (60.6%)	152 (67.0%)	108 (69.2%)	260 (67.9%)	165 (64.2%)	117 (59.4%)	282 (62.1%)
No	87 (39.5%)	61 (39.1%)	148 (39.4%)	75 (33.0%)	48 (30.8%)	123 (32.1%)	92 (35.8%)	80 (40.6%)	172 (37.9%)
Missing	104	103	207	97	103	200	67	62	129
Odds ratio (95%CI), p-value	1.02 (0.65, 1.60), p=0.9283			1.00 (0.65, 1.52), p=0.9884			1.12 (0.75, 1.68), p=0.5678		
Returned as part of:									
Graded return- to-work							35 (33.7%)	26 (34.7%)	
Supported work							2 (1.9%)	0 (0.0%)	
None							28 (26.9%)	31 (41.3%)	
Other							39(37.5%)	18(24.0%)	
Missing							61	42	
Secondary outcomes:	In those reporting return to work at follow-up								
Stroke impacted work status*	103/113 (91.2%)	73/85 (85.9%)	176/198 (88.9%)	78/127 (61.4%)	54/89 (60.7%)	132/216 (61.1%)	51/105 (48.6%)	34/77 (44.2%)	85/182 (46.7%)
Hours									
Change in working hours	66/108 (61.1%)	39/80 (48.8%)	105/188 (55.9%)	59/124 (47.6%)	33/87 (37.9%)	92/211 (43.6%)	41/103 (39.8%)	24/75 (32.0%)	65/178 (36.5%)
If yes, current working hours, M (SD)	18.3 (12.24), n=51	20.3 (12.15), n=35	19.1 (12.17), n=86	19.9 (11.11), n=31	24.2 (8.90), n=18	21.5 (10.47), n=49	28.4 (11.65), n=33	31.5 (11.71), n=15	29.4 (11.64), n=48

(Continued)

Table 2. (Continued)

	3 months			6 months			12 months		
	ESSVR (n = 324)	UC (n = 259)	Total (n = 583)	ESSVR (n = 324)	UC (n = 259)	Total (n = 583)	ESSVR (n = 324)	UC (n = 259)	Total (n = 583)
Pre-stroke working hours, M (SD)	41.2 (12.04), n = 118	37.3 (12.89), n = 78	39.7 (12.50), n = 196	38.7 (12.45), n = 135	38.5 (12.89), n = 94	38.6 (12.61), n = 229	39.0 (11.77), n = 145	39.3 (10.78), n = 103	39.1 (11.35), n = 248
Days worked									
Have had to take time off	91/111 (82.0%)	61/83 (73.5%)	152/194 (78.4%)	42/124 (34.4%)	31/85 (36.5%)	73/207 (35.3%)	22/98 (22.4%)	14/72 (19.4%)	36/170 (21.2%)
If yes, weeks taken off, M (SD)	10.2 (4.30), n = 78	10.3 (5.97), n = 54	10.2 (5.02), n = 132	6.7 (5.91), n = 32	5.9 (5.04), n = 23	6.3 (5.52), n = 55	13.5 (15.78), n = 15	7.8 (8.26), n = 11	11.1 (13.22), n = 26
Role									
Changed role	12/102 (11.8%)	9/75 (12.0%)	21/177 (11.9%)	12/122 (9.8%)	15/87 (17.2%)	27/209 (12.9%)	13/103 (12.6%)	9/76 (11.8%)	22/179 (12.3%)

Bold text related to estimated adjusted treatment effects.

*Over the past 3 months.

Table 3. Secondary Outcomes†.

	3 months			6 months			12 months		
	ESSVR (n = 324)	UC (n = 259)	Total (n = 583)	ESSVR (n = 324)	UC (n = 259)	Total (n = 583)	ESSVR (n = 324)	UC (n = 259)	Total (n = 583)
Questionnaire returned									
Mood: HADS-Anxiety [‡] , M (SD)	6.6 (4.38), n = 314	7.0 (4.65), n = 247	6.8 (4.50), n = 561	7.5 (4.86), n = 179	7.4 (4.45), n = 127	7.5 (4.66), n = 306	6.8 (5.01), n = 155	7.2 (4.56), n = 104	7.0 (4.71), n = 259
Normal (0–7)	187 (59.6%)	134 (54.3%)	321 (57.2%)	96 (53.6%)	64 (50.4%)	160 (52.3%)	182 (56.2%)	134 (51.7%)	316 (54.2%)
Mild (8–10)	67 (21.3%)	56 (22.7%)	123 (21.9%)	36 (20.1%)	32 (25.2%)	68 (22.2%)	6.8 (5.01), n = 155	7.2 (4.56), n = 104	7.0 (4.71), n = 259
Moderate (11–14)	45 (14.3%)	39 (15.8%)	84 (15.0%)	31 (17.3%)	24 (18.9%)	55 (18.0%)	6.8 (5.01), n = 155	7.2 (4.56), n = 104	7.0 (4.71), n = 259
Severe (15–21)	15 (4.8%)	18 (7.3%)	33 (5.9%)	16 (8.9%)	7 (5.5%)	23 (7.5%)	6.8 (5.01), n = 155	7.2 (4.56), n = 104	7.0 (4.71), n = 259
Mood: HADS-Depression [‡] , M (SD)	6.1 (3.94), n = 311	6.2 (4.18), n = 247	6.1 (4.04), n = 558	6.3 (4.38), n = 179	5.9 (3.98), n = 127	6.1 (4.18), n = 306	5.7 (4.59), n = 158	5.4 (4.13), n = 105	5.6 (4.13), n = 263

(Continued)

Table 3. (Continued)

	Baseline			3 months			6 months			12 months		
	ESSVR (n=324)	UC (n=259)	Total (n=583)	ESSVR (n=324)	UC (n=259)	MD (95%CI), p-value	ESSVR (n=324)	UC (n=259)	MD (95%CI), p-value	ESSVR (n=324)	UC (n=259)	MD (95%CI), p-value
Normal (0-7)	201 (64.6%)	156 (63.2%)	357 (64.0%)	108 (60.3%)	86 (67.7%)	194 (63.4%)	119 (66.1%)	90 (70.3%)	209 (67.9%)	114 (72.2%)	78 (74.3%)	192 (73.0%)
Mild (8-10)	68 (21.9%)	50 (20.2%)	118 (21.1%)	40 (22.3%)	21 (16.5%)	61 (19.9%)	35 (19.4%)	18 (14.1%)	53 (17.2%)	19 (12.0%)	15 (14.3%)	34 (12.9%)
Moderate (11-14)	32(10.3%)	31(12.6%)	63(11.3%)	20(11.2%)	18(14.2%)	38(12.4%)	17(9.4%)	17(13.3%)	34(11.0%)	16(10.1%)	9(8.6%)	25(9.5%)
Severe (15-21)	10 (3.2%)	10 (4.0%)	20 (3.6%)	11 (6.1%)	2 (1.6%)	13 (4.2%)	9 (5.0%)	3 (2.3%)	12 (3.9%)	9 (5.7%)	3 (2.9%)	12 (4.6%)
Functional ability: NEADL, M (SD)	61.4 (12.21), n=315	62.5 (11.04), n=252	61.9 (11.71), n=567				54.9 (13.08), n=179	56.3 (11.92), n=129	-1.05 (-3.96, 1.86), p=0.4755	54.3 (13.20), n=157	57.9 (10.75), n=109	-3.37(-6.26, -0.48), p=0.0230**
Participation: CIQ-R Social Integration, M (SD)	7.1 (1.89), n=315	7.1 (1.92), n=250	7.1 (1.90), n=565							6.0 (2.24), n=153	6.5 (2.16), n=109	-0.36 (-0.86, 0.13), p=0.1493
Participation: CIQ-R Productivity, M (SD)	5.6 (1.18), n=285	5.6 (1.22), n=234	5.6 (1.20), n=519							4.3 (2.04), n=149	4.6 (2.03), n=106	-0.40(-0.82, 0.01), p=0.0571
Work self-efficacy: WAI, M (SD)	3.7 (3.00), n=311	3.6 (3.07), n=246	3.6 (3.03), n=557	5.0 (3.14), n=182	5.4 (3.13), n=127	-0.44 (-1.06, 0.17), p=0.1551	6.0 (2.71), n=180	6.2 (3.07), n=129	-0.27 (-0.84, 0.30), p=0.3537	6.2 (3.08), n=154	6.6 (2.82), n=111	-0.45 (-1.18, 0.28), p=0.2226
Post-stroke confidence: CASIM, M (SD)	51.0 (13.09), n=312	50.9 (12.83), n=236	50.9 (12.97), n=548							51.2 (15.42), n=149	52.0 (13.89), n=104	-0.79 (-3.64, 2.06), p=0.5837
Carer burden: MSCI, M (SD)	9.0 (6.08), n=67	8.5 (6.23), n=61	8.7 (6.13), n=128	8.3 (6.47), n=37	7.7 (6.01), n=24	-0.27 (-2.08, 1.54), p=0.7681	7.5 (6.68), n=38	6.2 (5.37), n=18	0.87 (-1.59, 3.32), p=0.4858	8.1 (6.08), n=37	3.9 (4.31), n=17	2.52 (0.63, 4.41), p=0.0095**

[†]Bold text related to estimated treatment effects. MD (95% CI) represents the adjusted mean difference between treatment groups. ESSVR/UC. HADS scores range 0-21, higher scores indicate more severe anxiety/depression. NEADL scores range 0-66, higher scores indicate greater functional ability. CIQ-R Social Integration scores range 0-10, productivity scores 0-7; higher scores indicate greater community integration. WAI scores range 0-10, higher values indicate better work ability. CASIM Scores range 0-81, higher scores indicate greater confidence. MSCI scores range 0-26, higher scores indicate greater carer burden. ** indicates statistically significant effects.

[‡]Lower scores indicate better outcomes for measures with a [‡], otherwise higher scores indicate better outcomes.

ESSVR was co-developed with expert service users and providers following MRC guidance,²⁷ drawing on best available evidence and clinical guidelines at the time.^{41,42} It was valued by participants, OTs, and employers,³⁰ and compliance was good and fidelity acceptable.²²

Our seven PPI representatives met 6-monthly to define our primary outcome, inform research design, OT training, participant resources, troubleshoot issues, interpretation, and dissemination.⁴³

Limitations

The pandemic changed the health care and employment contexts in which ESSVR was delivered. It also changed the meaning of work in people's lives and influenced the "great retirement"⁴⁴ (Further details see supplementary material). It impacted RETAKE recruitment, intervention delivery, data collection, and follow-up. RETAKE paused to recruitment 1 week after the first UK COVID-19 lockdown was mandated with the trial completed in just 28.5% participants. Most post-COVID intervention delivery occurred online or by phone, rather than face-to-face as in the feasibility trial, with more time spent addressing current issues, and offering psychological support and increased difficulty engaging employers.²⁴ This was possibly in response to disruption caused to people's lives,⁴⁵ heightened anxiety,^{46,47} limited access to NHS services,⁴⁸ and COVID-19 symptoms, such as fatigue, possibly compounding that related to stroke.^{2,49} During the pandemic widespread implementation of telehealth across the NHS, changed rehabilitation delivery, raising concerns about digital exclusion.⁵⁰ It is possible that telehealth enabled UC further advantaged socially advantaged people with fewer disabilities. The impact of COVID-19 infection on work ability⁵¹ led to an NHS England-led nationwide initiative⁵² to develop resources for NHS health care professionals to support return-to-work following COVID-19 infection. This possibly equipped OTs with VR skills that were transferable to stroke.

The pandemic also impacted the employment context. Efforts to minimize COVID-19 spread³⁷ necessitated flexible home-based working and widespread implementation of videoconferencing software possibly advantaging the least disabled, and people conversant in and with access to technology. Efforts to facilitate remote working and support employees during lockdowns, coupled with heightened awareness of pandemic-related health inequity⁵³ and labor shortages,⁵⁴ may have expedited employer awareness of Equality, Diversity, and Inclusion. These changes compromised core intervention mechanisms (employer engagement and education, cross-boundary working, negotiating reasonable adjustments). The pandemic increased the length of the trial to over 5 years. In this time, new guidelines^{10,11,52} advocating the need for VR, highlighted the

need for "early intervention," and the Stroke Sentinel National Audit Program, introduced VR-specific questions to its audit, influencing changes in clinical practice.⁵⁵ Despite providing training and support to recruiting clinical research network staff, only 10% of participants were cognitively impaired and 17% had aphasia. High staff turnover,⁵⁶ and use of pre-recorded training resources following the pandemic, may have contributed. Interviews with recruiting teams highlighted varied perceptions regarding the appropriateness of recruiting patients "early after stroke."

Despite efforts to maintain participant engagement, full questionnaire completion was low with secondary outcomes missing for more than half the sample. Those lost to follow-up tended to represent more severe stroke, with differential missing data patterns by arm, limiting the reliability of comparison between groups on secondary outcomes. Reducing questionnaire length or collecting data via other means (i.e. medical records) may have improved completion rates. Contractual issues meant it was not possible to obtain aggregated non-identifiable data on work status via the DWP.

We were unable to explore the effect of contract type or flexible working in relation to outcomes, and recommend future data collection to include employment on zero hours contracts and ability to work remotely. The NIH Stroke Scale for quantifying stroke severity was not collected; therefore, we quantified using the number of impairments in mobility, aphasia, and cognition.

Future research directions

Younger age, high education, believing work is important and self-expectations of return-to-work are positive predictors for return to work^{57,58} (refs). These factors have undoubtedly influenced the findings of this trial, which recruited a predominantly male, relatively young (mean 54 years) and mild-to-moderate sample of stroke survivors and where intention to return-to-work was a trial inclusion criterion. Where resources are limited, our findings suggest ESSVR should be targeted, potentially at older patients and those with greater post-stroke impairment. Further research to confirm this finding is needed, as is research to better understand the needs of people with aphasia, less well-educated stroke survivors on lower incomes and younger stroke survivors with little or no residual disability who are able to self-advocate and motivated to return.

Longer follow-up studies are needed. Future trials should consider minimizing data collection to reduce participant burden, and resourcing data collection support for those who need it; stratify by stroke severity; and comprehensively document UC. Involving PPI members in training recruiters may also help overcome recruitment bias.

Conclusion

The quantitative findings from this first definitive RCT of a stroke specialist VR intervention found no evidence of benefit of ESSVR on return-to-work. The pandemic changed the world of work irreversibly, and health care delivery beyond anything that could have been anticipated in the trial lifetime. It changed the meaning of work in people's lives, increasing rates of early retirement, and compromised key ESSVR mechanisms, the overall effectiveness of the intervention, our primary outcome, and trial delivery.

Acknowledgements

The authors thank the 583 participants and 21 NHS stroke services involved in the study, the Trial Steering Committee for support throughout, treating OTs, research assistants, and CTRU staff Marissa Arfan, Andrew Carter, Richard Brindle, Tom Morris, Alison Fergusson, Joe Hill. They thank wider members of the RETAKE research group: former members Vicki McLellan, Suzanne Hartley, Ivana Holloway, Bonnie Cundill, Sara Clarke, Professor Marion Walker; additional patient and public involvement partners Margaret Cheng, Tony Boyce, Isabella Iyama, Martin Coult; and Occupational Therapy Mentors Ruth Tyerman, Yash Bedekar, Jo Hurford.

Author contributions

K.A.R., A.J.F., A.B., R.J.O.C., T.H.S., C.M., D.J.C., J.S., J.D.M., and C.W. conceived the study. J.P., J.H., K.P., E.T., and F.D. operationalized the protocol. J.H., J.P., K.A.R. designed the intervention. K.A.R., D.J.C., and C.M. designed the process evaluation. K.A.R., C.M., D.J.C., D.T., K.C., J.H., J.P., and K.P. operationalized the process evaluation protocol. A.W.H., E.T., and A.J.F. implemented the data management and statistical analysis plan. T.H.S. designed the health economics plan; S.P., H.R., and R.C. implemented the health economics plan. J.S., C.M., and J.M. acted as PPI collaborators to support plans for trial design/delivery, management, and dissemination of trial findings. K.A.R. had overall responsibility in their role as chief investigator. A.W.H. and E.T. had full access to, and verified, all the data in the study. K.A.R. and A.W.H. drafted the article; all authors read and approved the final version.

Declaration of conflicting interest

The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article:

K.A.R., A.B., A.J.F., C.M., C.W., R.J.O.C., and T.H.S. were awarded NIHR HTA grant funding (15/130/11) for the RETAKE Trial. K.A.R., K.P., A.B., J.P., A.J.F., A.W.H., E.T., D.J.C., D.T., K.C., C.M., C.W., R.J.O.C., J.H., S.P., H.R., R.C., T.H.S., and F.D. were paid a proportion of their salary from the NIHR HTA grant funding the RETAKE trial.

A.B., A.J.F., A.W.H., C.W., F.D., K.A.R., R.J.O.C., R.C., and H.R. report other grant funding from NIHR. K.A.R. and J.H. were unpaid advisors to NHS England in development of a toolkit for NHS professionals to support return-to-work after stroke. J.H. was the Chair of the Royal College of OTs Specialist Section

Work from 2019 to present, received royalty payments for a book "Vocational Rehabilitation" published in 2007, and reports grant funding from RCOT. K.A.R. was a member of the HTA Clinical Evaluation and Trials panel between 2017 and 2021. K.A.R. also received funding from EPSRC, Elisabeth Casson Trust, Ossie Newell Foundation, MRFF. A.J.F. was a member of the NIHR HTA Clinical Evaluation and Trials panel until 2018, NIHR Clinical Trials Unit Standing Advisory Committee (2022), and the NIHR COVID Prophylaxis Platform Study in Care Homes Funding Committee in 2020. A.W.H. was a committee member for the NIHR RfPB. C.W. was the Implementation Lead for the NIHR ARC NWC. A.B. also received funding from Wellcome Trust, Stroke Association. R.J.O.C. is a Member of the Clinical Reference Group on Rehabilitation, Disability and Spinal Cord Injury, NHS England. T.H.S. was the chair of an NIHR RfPB Committee to 2024 and member of various NIHR HTA committees between 2013 and 2019. A.J.F., A.W.H., and C.W. report independent membership on NIHR and charity-funded Data Monitoring and Advisory Committees.

The views expressed are those of the authors and not necessarily those of the NHS, NIHR, or the Department of Health and Social Care.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: National Institute for Health Research Health Technology Assessment (NIHR-HTA) 15/130/11

Data sharing

Data supporting this work are available on reasonable request. All requests will be reviewed by relevant stakeholders, based on the principles of a controlled access approach. Requests to access data should be made to CTRU-DataAccess@leeds.ac.uk in the first instance.

ORCID iDs

A Wright-Hughes  <https://orcid.org/0000-0001-8839-6756>

K Powers  <https://orcid.org/0000-0001-7276-7073>

C Watkins  <https://orcid.org/0000-0002-9403-3772>

RJ O'Connor  <https://orcid.org/0000-0002-4643-9794>

S Pyne  <https://orcid.org/0000-0003-0093-9125>

Supplemental material

Supplemental material for this article is available online.

References

1. Stroke Association. Stroke statistics, 2022, <https://www.stroke.org.uk/stroke/statistics#UK%20summary>
2. GBD 2019 Stroke collaborators. Global, regional, and national burden of stroke and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet Neurol* 2021; 20: 795–820.
3. Patel A, Berdunov V, King D, Quayyum Z, Wittenberg R and Knapp M. Current, future and avoidable costs of stroke in the UK. *Stroke Association*, 2017, <https://www.stroke.org>.

- uk/sites/default/files/costs_of_stroke_in_the_uk_summary_report_0.pdf
4. Sen A, Bisquera A, Wang Y, et al. Factors, trends, and long-term outcomes for stroke patients returning to work: the South London stroke register. *Int J Stroke* 2019; 14: 696–705.
 5. Edwards JD, Kapoor A, Linkewich E and Swartz RH. Return to work after young stroke: a systematic review. *Int J Stroke* 2018; 13: 243–256.
 6. Martin-Saez MM and James N. The experience of occupational identity disruption post stroke: a systematic review and meta-ethnography. *Disabil Rehabil* 2021; 43: 1044–1055.
 7. Waddell G and Burton AK. Is work good for your health and well-being? 2006, <https://cardinal-management.co.uk/wp-content/uploads/2016/04/Burton-Waddell-is-work-good-for-you.pdf>
 8. Mousteri V, Daly M and Delaney L. The scarring effect of unemployment on psychological well-being across Europe. *Soc Sci Res* 2018; 72: 146–169.
 9. Department of Work and Pensions; Department of Health and Social Care; The Rt Hon David Gauke and The Rt Hon Jeremy Hunt MP. Improving lives: the future of work, health and disability, 2017, <https://www.gov.uk/government/publications/improving-lives-the-future-of-work-health-and-disability>
 10. NICE. Stroke rehabilitation in adults. *NICE guideline*, 2023, www.nice.org.uk/guidance/ng236
 11. Intercollegiate Stroke Working Party. National clinical guideline for stroke for the UK and Ireland, 2023 Edition, www.strokeguideline.org
 12. British Society of Rehabilitation Medicine. Vocational rehabilitation: The way forward. *A working party report commissioned by the British Society of Rehabilitation Medicine*, 2000, https://archive.org/details/vocationalrehab0000unse_g513
 13. Pearce G, O'Donnell J, Pimentel R, et al. Interventions to facilitate return to work after stroke: a systematic review. *Int J Environ Res Public Health* 2023; 20: 6469.
 14. Ntsiea MV, Van Aswegen H, Lord S and Olorunju S S. The effect of a workplace intervention programme on return to work after stroke: a randomised controlled trial. *Clin Rehabil* 2015; 29: 663–673.
 15. Grant M. *Developing, delivering and evaluating stroke specific vocational rehabilitation: a feasibility randomised controlled trial*. PhD thesis, University of Nottingham, Nottingham, 2016.
 16. Phillips J, Gaffney K, Phillips M and Radford K. Return to work after stroke—feasibility of 6-year follow-up. *Brit J Occup Therapy* 2019; 82: 27–37.
 17. Radford KA, Craven K, McLellan V, et al. An individually randomised controlled multi-centre pragmatic trial with embedded economic and process evaluations of early vocational rehabilitation compared with usual care for stroke survivors: study protocol for the RETurn to work After stroke (RETAKE) trial. *Trials* 2020; 21: 1–17.
 18. Pyne S, Sach TH, Cameron R, et al. Cost consequences analysis of early vocational rehabilitation compared with usual care for stroke survivors. *Clin Rehab* Epub ahead of print 5 December 2024. doi:10.1177/02692155241299372.
 19. Clarke DJ, Powers K, Trusson D, et al. The RETurn to work After stroke (RETAKE) trial: findings from a mixed-methods process evaluation of the Early Stroke Specialist Vocational Rehabilitation (ESSVR) intervention. *PLoS ONE* 2024; 19: e0311101.
 20. Craven K, Holmes J, Powers K, et al. Embedding mentoring to support trial processes and implementation fidelity in a randomised controlled trial of vocational rehabilitation for stroke survivors. *BMC Med Res Methodol* 2021; 21: 1–15.
 21. Powers K, das Nair R, Farrin A, et al. Assessing fidelity to early stroke specialist vocational rehabilitation. Submitted to *Trials*.
 22. Powers KE, das Nair R, Phillips J, Farrin A and Radford KA. Exploring the association between individual-level attributes and fidelity to a vocational rehabilitation intervention within a randomised controlled trial. *Int J Environ Res Public Health* 2023; 20: 4694.
 23. Trusson D, Powers K, Radford K, et al. Experiences of support to return to work: longitudinal case-studies from the RETurn to work after stroke (RETAKE) trial. *NIHR HTA Journal* (under review).
 24. Radford KA, Grant MI, Holmes JA, et al. Development and description of the Early Stroke Specialist Vocational Rehabilitation (ESSVR) intervention delivered in the Return to work after stroke (RETAKE) Trial. *NIHR HTA Journal* (under review).
 25. Radford KA, McKevitt C, Clarke S, et al. RETurn to work After stroke (RETAKE) Trial: protocol for a mixed-methods process evaluation using normalisation process theory. *BMJ Open* 2022; 12: e053111.
 26. Demeyere N, Riddoch MJ, Slavkova ED, et al. The Oxford cognitive screen (OCS): validation of a stroke-specific short cognitive screening tool. *Psychol Asses* 2015; 27: 883.
 27. Skivington K, Matthews L, Simpson SA, et al. A new framework for developing and evaluating complex interventions: update of Medical Research Council guidance. *BMJ* 2021; 374: n2061.
 28. De Dios Pérez B, Merchan J, Powers K, et al. How does mentoring occupational therapists improve intervention fidelity in a randomised controlled trial? A realist evaluation. *BMC Med Res Methodol* 2024; 24: 142.
 29. Powers K, Clarke S, Phillips J, et al. Developing an implementation fidelity checklist for a vocational rehabilitation intervention. *Pilot Feasibil Stud* 2022; 8: 234.
 30. Zigmond AS and Snaith RP. The hospital anxiety and depression scale. *Acta Psychiatrica Scand* 1983; 67: 361–370.
 31. Nouri F and Lincoln N. An extended activities of daily living scale for stroke patients. *Clin Rehab* 1987; 1: 301–305.
 32. Willer B, Ottenbacher KJ and Coad ML. The community integration questionnaire: a comparative examination. *Am J Phys Med Rehabil* 1994; 73: 103–111.
 33. Ilmarinen J and Tuomi K. Work ability index for aging workers. *Helsinki Finnish Inst Occup Health* 1993; 35: 142–151.
 34. Horne J. *Measuring confidence after stroke*. Nottingham: University of Nottingham, 2016.
 35. Thornton M and Travis SS. Analysis of the reliability of the modified caregiver strain index. *J Gerontol B Psychol Sci Soc Sci* 2003; 58: S127–32.
 36. Candlish J, Teare MD, Dimairo M, et al. Appropriate statistical methods for analysing partially nested randomised controlled trials with continuous outcomes: a simulation study. *BMC Medical Research Methodology* 2018; 18: 1–17.

37. Impact assessment. Coronavirus Job Retention Scheme, 2022, <https://www.gov.uk/government/publications/coronavirus-job-retention-scheme-screening-equality-impact-assessment/coronavirus-job-retention-scheme>
38. Trygged S, Ahacic K and Kåreholt I. Income and education as predictors of return to working life among younger stroke patients. *BMC Public Health* 2011; 11: 1–9.
39. Cohen J. *Statistical power analysis for the behavioral sciences*. 2nd ed. London: Routledge, 1988.
40. McGill K, Sackley CM, Godwin J, et al. A systematic review of the efficiency of recruitment to stroke rehabilitation randomised controlled trials. *Trials* 2020; 21.
41. Donker-Cools BH, Daams JG, Wind H and Frings-Dresen MH. Effective return-to-work interventions after acquired brain injury: a systematic review. *Brain Inj* 2016; 30: 113–131.
42. National Institute for Health Care Excellence (NICE). Stroke rehabilitation in adults: NICE guideline [CG162], 2013, <https://www.nice.org.uk/guidance/cg162> (accessed 1 October 2019).
43. Radford KA, Wright-Hughes A, Clarke D, et al. RETurn to work after stroKE (RETAKE) 15/130/11. Synopsis submitted to Health Technology Assessment (under review).
44. Insights P. What is driving the Great Retirement? 2022, <https://www.thephoenixgroup.com/phoenix-insights/publications/what-driving-great-retirement/>
45. Trusson D, Powers K, Radford KA, et al. Exploring stroke survivor and employer experiences of return-to-work support within the RETurn to work After stroKE (RETAKE) trial during the COVID-19 pandemic. submitted to *Frontiers in Sociology*.
46. Santomauro DF, Herrera AMM, Shadid J, et al. Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic. *Lancet* 2021; 398: 1700–1712.
47. World Health Organization. *Mental health and COVID-19: early evidence of the pandemic's impact: scientific brief*, 2 March 2022. Geneva: World Health Organization, 2022.
48. British Medical Association. *Delivery of healthcare during the pandemic BMA Covid Review 3*. London: British Medical Association, 2022.
49. Abdul Rashid MR, Syed Mohamad SN, Tajjudin AIA, et al. COVID-19 pandemic fatigue and its sociodemographic, mental health status, and perceived causes: a cross-sectional study nearing the transition to an endemic phase in Malaysia. *Int J Environ Res Public Health* 2023; 20: 4476.
50. NHS England. Inclusive digital healthcare: a framework for NHS action on digital inclusion, 2023, <https://www.england.nhs.uk/long-read/inclusive-digital-healthcare-a-framework-for-nhs-action-on-digital-inclusion/>
51. Office for National Statistics. Rising ill-health and economic inactivity because of long-term sickness, UK: 2019 to 2023, <https://www.ons.gov.uk/employmentandlabourmarket/peopleinwork/economicinactivity/articles/risingillhealthandeconomicinactivitybecauseoflongtermsicknessuk/2019to2023>
52. NHS England. Stroke vocational rehabilitation toolkit, <https://www.e-lfh.org.uk/programmes/strokevrtoolkit/>
53. Marmot M. Health equity in England: the Marmot review 10 years on. *BMJ* 2020; 368: m693.
54. Causa O, Abendschein M, Luu N, Soldani E and Soriolo C. The post-COVID-19 rise in labour shortages, 2022, https://www.oecd-ilibrary.org/economics/the-post-covid-19-rise-in-labour-shortages_e60c2d1c-en
55. Sentinel Stroke National Audit Programme (SSNAP). Post-acute organisational audit report national report, Section 7: vocational rehabilitation, 2021, <https://www.strokeaudit.org/Documents/National/PostAcuteOrg/2021/2021-PAOrgPublicReport.aspx>
56. Care Quality Commission. The state of health care and adult social care in England 2022/23, www.gov.uk/official-documents2023
57. Westerlind E, Persson HC, Eriksson M, Norrving B and Sunnerhagen KS. Return to work after stroke: a Swedish nationwide registry-based study. *Acta Neurol Scand* 2020; 141: 56–64.
58. Rosendahl E, Carlson N, Kragholm K, et al. Education and age in return to work after ischemic stroke: a Danish nationwide registry-based cohort study. *Neurologist* 2024; 101097.